MeTA Phase I: Where are we? MeTA18/06/20161. MeTA2 The MeTA Phase I Proposal Purpose To pilot a new multi-stakeholder approach towards increasing transparency.

Slides:



Advertisements
Similar presentations
Saul Walker Policy and Research Division, DFID Jordan 4 December, 2007 Medicines Transparency Alliance (MeTA)
Advertisements

Delivering Solutions – R esponding to market realities in developing countries WTO Symposium, Geneva, 16 June 2003 Ritu Kumar Sustainable Trade and Innovation.
Good governance for water, sanitation and hygiene services
1 African ICT Roadmap to Achieve NEPAD Objectives Arusha, Tanzania, 1-3 April 2003 Roles of Government and ATU in the Implementation of NEPAD ICT objectives.
Framework for K-Farm Green Value Chain Production of Carambola
Group 3 Irrational use of Medicine and medical technology.
World Health Organization
Sakthivel Selvaraj, Habib Hasan, Preeti Kumar, Maulik Chokshi Public Health Foundation of India, India 1.
First Evaluation of Good Governance for Medicines Programme Brief Summary of Findings.
Presented to CSO workshops in Kabwe on 18 July 2014, Livingstone on 28 July 2014 and Lusaka on 27 August 2014.
Medicines Transparency Alliance (MeTA) Presented to CSO workshops during 2013 in SOLWEZI AUGUST 27 NDOLA AUGUST 29 LUSAKA OCTOBER 22.
Rational Use of Injections within National Drug Policies World health organisation Essential Drugs and Medicines Policy Safe Injection Global Network Cairo.
Medicines Transparency Alliance Presented by Deirdre Dimancesco Department of Essential Medicines and Health Products, WHO at the Technical Briefing Seminar.
Action for Global Health, Sala Capranichetta, Piazza Montecitorio, 125, Rome, 9 th February |1 | by David B Evans, Director Department of Health.
Towards an Integrity Standard in the Pharmaceutical Industry IACC Conference, May 27, 2003 Seoul, Korea Dr. Jillian Clare Cohen Assistant Professor, Leslie.
Birgit Kerstens 1, Samia Saad 2, Wilbert Bannenberg 1,2 1 Health Research for Action (HERA), Belgium; 2 Medicines Transparency Alliance (MeTA) Pilot, United.
1. SITA’S TRANSFORMATION PATH TO MAXIMIZE ICT VALUE TO GOVERNMENT Keynote address by Ms Nontobeko Ntsinde Acting Chief Executive Officer State Information.
Division for Freedom of Expression, Democracy and Peace A presentation by Mogens Schmidt DADG for Communication & Information Sector.
UNDP & the Business SectorBureau for Resources and Strategic Partnerships Business, sustainable development and the MDGs: A changing landscape.
AIM 2030 Access to Innovative Medicines Draft concept for a new World Bank-led multi-stakeholder initiative August 2014, Andreas Seiter.
New Procurement & Delivery Arrangements for the Schools’ Estate Presentation to Strategic Advisory Group 18 April 2005.
MeTA Jordan Executive Summary Baseline data is an important source for policy makers to diagnose the pharmaceutical and health sector situation in order.
© Cambridge University Press 2012 AREA OF STUDY 2 UNIT 4 MANAGING PEOPLE AND CHANGE CHAPTER 14 CORPORATE SOCIAL RESPONSIBILTY AND BUSINESS ETHICS THE MANAGEMENT.
The global voice of savings and retail banking March 2010 Bangalore, India Mr. Adinan Maning GM/Chief Executive, Bank Simpanan Nasional, Malaysia.
A Global Transparency Program for the Construction Sector Christiaan Poortman Chairman, CoST International Advisory Group 7 October, 2010.
MULTI-STAKEHOLDER COLLABORATION: CAN IT IMPROVE TRANSPARENCY, DISCLOSURE AND ACCESS TO MEDICINES? EXPERIENCES FROM 7 META PILOT COUNTRIES Wilbert Bannenberg.
Wilbert Bannenberg, Technical Director MeTA International Secretariat IACC 14 Bangkok, 13 November 2010 MeTA multi-stakeholder process – a way to improve.
Wilbert Bannenberg SARPAM
Medicines Transparency Alliance01/10/2015 Availability of Medicines Anita Wagner Harvard Medical School & WHO Collaborating Center in Pharmaceutical Policy.
Data Disclosure: An Ongoing Progress Towards Transparency Abeer Rabayah B.Sc Pharmacy -MBA /Marketing MeTA National Coordinator.
Medicines Transparency Alliance03/10/ MeTA Zambia Violet Kabwe MeTA Zambia Consultant.
–What Should CSR Really Look Like? –Is CSR appropriate answer to today's challenges? Pierre Echard Director, CSR Europe network of National Partner Organisations.
The policy development for introducing of the oral fluid based rapid HIV test kit in Thailand Writers in the 2009 Write Workshop (WHO Bulletin)
Contact Monitoring Regional Network (CMKN). Why procurement It is estimated that an effective public procurement system could save as much as 25% of government.
UNIDO Green Industry Platform Prep- Meeting Vienna, 3. Mai 2012 Heinz Leuenberger PhD Director, Environmental Management Branch.
Medicines Transparency Alliance14/10/ Medicines promotion: innovative tools to promote rational use Carole Piriou Project officer Rational use of.
1 Towards a Medicines Transparency Alliance (MeTA) Richard Laing and Ali Cameron with slides prepared by Michael Borowitz, DfID WHO Technical Briefing.
4 th - 18 November 2011 ICIUM 2011 Conference Antalya, Turkey 16/10/2015.
Reproductive Health Supplies Coalition Meeting Washington DC November 2004.
Medicines Transparency Alliance - Zambia Billy Mweetwa Country Medicines Advisor – Zambia.
Slide 1 Win-Win or Lose-Lose? Why is multi-stakeholder involvement essential? Saul Walker Senior Health Advisor UK Department for International Development.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
Medicines Transparency Alliance27/10/ MeTA Ghana Augustina Koduah (Mrs) Country Coordinator.
Non-Governmental Organizations
MeTA Medicines Transparency Alliance: Under New Management Dr Tim Reed Director, Health Action International (Global) International MeTA Secretariat.
Brussels, May 2008MDA Update, RHSC membership meeting Market Development Approaches Working Group Update November 2007 – May 2008 Ben Light MDAWG Leader,
Medicines Transparency Alliance31/10/ MeTA Zambia – Pricing Goodwell Lungu MeTA Secretary General.
Yemaneberhan Taddesse.  PASDEP(plan of accelerated and sustainable development for the Eradication of poverty) Poverty reduction strategy is the main.
© 2010 AT&T Intellectual Property. All rights reserved. AT&T and the AT&T logo are trademarks of AT&T Intellectual Property. Operation Hand Salute AT&T.
SARPAM Southern African Regional Programme for Access to Medicines and Diagnostics Presentation to Botswana TRIPS and Access to Medicines workshop 26 March.
WHO-Technical Briefing Seminar | October-November 2012 Dr Cécile Macé 1 |1 | Good Governance for Medicines Programme Dr Cécile Macé EMP/MPC.
Raksha Sharda CUTS International 1 st National Reference Group (NRG) Meeting, India 24 th July,
Medicines Transparency Alliance Presented by Gilles Forte Department of Essential Medicines and Health Products, WHO On behalf of WHO and HAI Technical.
CoST Construction Sector Transparency Initiative (CoST) Bethan Grillo, CoST international secretariat IACC, 1 November 2008.
Regulation Inside Government: Approach and lessons learned Punita Goodfellow, Better Regulation Executive, Cabinet Office, UK.
COLLABORATIVE A credible group of organisations working together strategically, to maximise their operational synergies. To be universally acknowledged.
Defining Marketing for 21 st century. What is Marketing? “ marketing is about identifying and meeting human and social needs with profit” “marketing includes.
Wilbert Bannenberg & Elodie Brandamir Technical & Operational Directors MeTA International Secretariat MeTA Kyrgyzstan Forum Bishkek, 16 April 2009 Medicines.
Wilbert Bannenberg Technical Director, Intl MeTA Secretariat 28 April 2010, IPC meeting, Copenhagen Medicines Transparency Alliance: improving people’s.
45 th Session Advisory Committee on Health Research of the Pan American Health Organization (CAIS) Hamilton, ON, Canada 17 – 19 October 2012 Partnerships.
The Roadmap for Health Measurement and Accountability and Call to Action.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Existing Programs to support development of micro-enterprise for informal economy workers and other poverty reduction programs 16 March 2012 Banyan tree.
The Medicines Transparency Alliance Saul Walker Senior Policy Advisor, Access to Medicines Health Services Team.
Convening today at TIFR, Mumbai on 29th January, 2017, on the occasion of the Tata Memorial Centre Platinum Jubilee Conference – ‘Healthcare – a commodity.
SADC Medicines Database (SMD)
Wilbert Bannenberg SARPAM
BUDESHI PROGRAM DIRECTOR PUBLIC AND PRIVATE DEVELOPMENT CENTRE (PPDC)
Global Health Information Technology
Strategic development goals and priorities of the Republic of Tajikistan . National monitoring and evaluation system for their achievements. Eshboev.
Presentation transcript:

MeTA Phase I: Where are we? MeTA18/06/20161

MeTA2 The MeTA Phase I Proposal Purpose To pilot a new multi-stakeholder approach towards increasing transparency around the selection, regulation, procurement, sale and distribution of medicines in developing countries, thereby strengthening governance, improving efficiency, and encouraging innovative and responsible business practices

18/06/2016MeTA3 7 Pilot Countries … pioneers, leaders, champions – innovators!

3 key stakeholder sectors Public: (ministries – not only Health; health service managers and facilities; regulatory agencies; health and welfare insurance schemes) Private: (manufacturers; wholesalers; distributors; retailers; private practitioners and services; private health insurance; investors) Civil society: (communities, patients, consumers, transparency and rights groups, media, faith-based organisations)

One goal Increased access to essential medicines by poor people by: – shifting some decision making power – Increasing competitive pressure on suppliers – Improving the effectiveness of the supply chain – promoting better governance – ensuring more appropriate resource allocation – encouraging innovative and responsible business practices – Increasing the voice of patients and consumers And improving people’s health!

3 key points of Phase I 1. Country structure and commitment 2. Transparency: disclosure, data collection and analysis 3. Accountability: multi-stakeholder approach and good governance

Key Point 2: Transparency Data Collection and Dissemination 1. Data on the quality and registration status of medicines 2. Data about the availability of medicines 3. Medicines price data 4. Policies concerning the ethical promotion of medicines

18 months planning and consensus building 7 countries commit politically Growing list of international stakeholders who support the concept International Secretariat in place International Advisory Group underway International launch – “2 nd phase of the peaceful revolution in international public health” now underway! Achievements so far MeTA18/06/20168

MeTA9 Thank You